Agios Pharmaceuticals Inc expected to post a loss of $1.60 a share - Earnings Preview

Agios Pharmaceuticals

30/07/2024 20:02

* Agios Pharmaceuticals Inc  AGIO.OQ   AGIO.O  is expected
to show
a rise in quarterly revenue when it reports  results on August 1
for the period ending June 30 2024
    * The Cambridge Massachusetts-based  company is expected to
report
a 38.7% increase in revenue to $9.307 million from $6.71 million
a year ago, according to the mean estimate from 8 analysts,
based on LSEG data.
    * ​LSEG's mean analyst estimate for Agios Pharmaceuticals
Inc is
for a loss of $1.60 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Agios
Pharmaceuticals Inc is $53.00​, above​ its last closing price
of $47.43. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Mar. 31 2024  -1.64       -1.65      -1.45     Beat    12.1
 Jan. 1 2024   -1.65       -1.65      -1.72     Missed  -4.4
 Sep. 30 2023  -1.72       -1.70      -1.64     Beat    3.7​
 Jun. 30 2023  -1.53       -1.56      -1.51     Beat    3.3
 ​​Mar.        -1.71       -1.70      -1.47     Beat    13.6
 31 2023                                                
 Jan. 1 0001   -1.60       -1.62      0.67      Beat    141.5​
 Sep. 30 2022  -1.73       -1.76      -1.49     Beat    15.5
 Jun. 30 2022  -1.76       -1.75      -1.68     Beat    3.8
 This summary was machine generated July 30 at 19:02 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)